(Reuters) – Eli Lilly and Co has agreed to acquire Point Biopharma Global in an all-cash deal valued at $1.4 billion, the two companies said on Tuesday. (Reporting by Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)
Business
Eli Lilly to buy Point Biopharma for $1.4 billion
(Reuters) – Eli Lilly and Co has agreed to acquire Point Biopharma Global in an all-cash deal valued at $1.4 billion, the two companies said on Tuesday.
(Reporting by Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)